IP Library Granted Patent US 6,943,146
Granted Patent B2
US 6,943,146 · App. 10/275,997 · Granted Sep 13, 2005

Method for promoting neovascularization

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,943,146
App. No.
10/275,997
Granted
Sep 13, 2005
Kind
B2
Abstract

The present invention relates to a method for enhancing angiogenic activity to promote neovascularization comprising administering to a subject a formulation comprising a synergistically effective amount of a TWEAK agonist and an angiogenic factor.

Claims (9)

1. A method for enhancing endothelial cell proliferation in an in vitro culture comprising the step of adding to said culture, a synergistically effective amount of TWEAK and basic fibroblast growth factor (bFGF).

2. A method for enhancing angiogenic activity in a mammal to promote neovascularization comprising the step of administering to said mammal a synergistically effective amount of TWEAK and basic fibroblast growth factor (bFGF).

3. The method according to claim 2 , wherein said method is used in the treatment of a myocardial ischemic condition in said mammal.

4. The method according to claim 2 , wherein said method is used to promote wound healing in said mammal.

5. The method according to claim 1 or 2 , wherein said TWEAK is a soluble recombinant TWEAK protein.

6. The method according to claim 1 or 2 , wherein said synergistically effective amount comprises basic fibroblast growth factor (bFGF) and TWEAK in a weight per weight ratio of at least about 1:100 to about 1:200.

7. The method according to claim 2 , wherein said method is used to promote neovascularization of transplanted or grafted tissues or organs in said mammal.

8. The method according to any one of claims 2 , 3 , 4 or 7 , wherein said mammal is a human.

9. The method according to any one of claims 2 , 3 , 4 or 7 , wherein said TWEAK and said basic fibroblast growth factor (bFGF) are administered by a route selected from the group consisting of: local injection, topical administration, parenteral administration, intranasal administration, intratracheal administration, pulmonary administration, oral administration, intravenous administration, intramuscular administration and subcutaneous administration.

Assignments (4)
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
CHANGE OF NAME Recorded Apr 16, 2007
From: BIOGEN, INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 019161/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2005
From: JAKUBOWSKI, ANIELA; BURKLY, LINDA
To: BIOGEN, INC.
Reel/Frame 015618/0086 →
CHANGE OF NAME Recorded Apr 15, 2004
From: BIOGEN IDEC MA, INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 014520/0982 →